Patents Assigned to Lupin Limited
-
Patent number: 9670262Abstract: The present invention relates to modified SAK gene having amino acid SEQ ID 2. The present invention further relates to process for cloning and expressing modified SAK gene fusion protein which imparts improved stability to the heterologous protein of interest. Further the invention relates to process of purification of recombinant heterologous proteins from bacterial inclusion bodies using modified SAK.Type: GrantFiled: August 28, 2014Date of Patent: June 6, 2017Assignee: LUPIN LIMITEDInventors: Shardul Salunkhe, Bhaskarjyoti Prasad, Praveen Muneshwar, Anjali Apte Deshpande, Sriram Padmanabhan
-
Publication number: 20170152298Abstract: The present invention relates to the purification of TNFR:Fc fusion protein. More specifically related to process of purification of TNFR:Fc fusion protein wherein the HCP is reduced. The present invention is directed to the use of mixed-mode chromatography and/or affinity chromatography to produce TNFR:Fc fusion protein which is substantially free of at least one of the protein degrading enzyme present in HCP.Type: ApplicationFiled: June 13, 2015Publication date: June 1, 2017Applicant: LUPIN LIMITEDInventors: Abir BANERJEE, Chandranath GANAPATHY, Sorab Rustom MODY, Ashok MISHRA
-
Publication number: 20170137421Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R4, and n are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PI3K enzyme of a subject.Type: ApplicationFiled: July 1, 2015Publication date: May 18, 2017Applicant: Lupin LimitedInventors: Manojkumar Ramprasad Shukla, Nirmal Kumar Jana, Sachin Jaysing Mahangare, Prashant Popatrao Vidhate, Dipak Raychand Lagad, Anand Jagannath Tarage, Sanjeev Anant Kulkarni, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20170112840Abstract: The present invention is related to heteroaryl compounds as MEK inhibitors. The invention includes heteroaryl compounds of formula I, their tautomers and pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them.Type: ApplicationFiled: January 6, 2017Publication date: April 27, 2017Applicant: LUPIN LIMITEDInventors: Bhavesh DAVE, Rakesh Kumar BANERJEE, Samiron PHUKAN, Abhijit Datta KHOJE, Rajkumar HANGARGE, Jitendra Sambhaji JADHAV, Venkata P. PALLE, Rajender Kumar KAMBOJ
-
Publication number: 20170101408Abstract: The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of formula I, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment.Type: ApplicationFiled: December 22, 2016Publication date: April 13, 2017Applicant: LUPIN LIMITEDInventors: Bhavesh DAVE, Rakesh Kumar BANERJEE, Samiron PHUKAN, Abhijit Datta KHOJE, Rajkumar HANGARGE, Jitendra Sambhaji JADHAV, Venkata P. PALLE, Rajender Kumar KAMBOJ
-
Patent number: 9617211Abstract: Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly ?7 subtype, its tautomeric forms, its stereoisomers, its pharmaceutically acceptable salts, its pharmaceutical composition, and its combinations with suitable medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.Type: GrantFiled: January 13, 2014Date of Patent: April 11, 2017Assignee: Lupin LimitedInventors: Neelima Sinha, Navnath Popat Karche, Anil Kashiram Hajare, Baban Rupaji Thube, Dnyaneshwar Changdeo Bhanage, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9617210Abstract: Disclosed are compounds of the Formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and m are as described herein, as modulators of the nicotinic acetylcholine receptors, particularly the ?7 subtype, their tautomeric forms, stereoisomers, and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, and combinations thereof with suitable other medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and/or treatment of disorders such as Alzheimer's disease, mild cognitive impairment, and senile dementia.Type: GrantFiled: March 12, 2014Date of Patent: April 11, 2017Assignee: Lupin LimitedInventors: Neelima Sinha, Navnath Popat Karche, Shridhar Keshav Adurkar, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9573944Abstract: The present invention is related to heteroaryl compounds as MEK inhibitors. The invention includes heteroaryl compounds of formula I, their tautomers and pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them.Type: GrantFiled: March 11, 2013Date of Patent: February 21, 2017Assignee: Lupin LimitedInventors: Bhavesh Dave, Rakesh Kumar Banerjee, Samiron Phukan, Abhijit Datta Khoje, Rajkumar Hangarge, Jitendra Sambhaji Jadhav, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9555035Abstract: The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of formula I, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment.Type: GrantFiled: July 25, 2016Date of Patent: January 31, 2017Assignee: Lupin LimitedInventors: Bhavesh Dave, Rakesh Kumar Banerjee, Samiron Phukan, Abhijit Datta Khoje, Rajkumar Hangarge, Jitendra Sambhaji Jadhav, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9504680Abstract: Disclosed are compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and m are as described herein, as modulators of the nicotinic acetylcholine receptors, particularly the ?7 subtype, their tautomeric forms, stereoisomers, and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, and combinations thereof with suitable other medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and/or treatment of disorders such as Alzheimer's disease, mild cognitive impairment, and senile dementia.Type: GrantFiled: June 16, 2014Date of Patent: November 29, 2016Assignee: Lupin LimitedInventors: Neelima Sinha, Navnath Popat Karche, Shridhar Keshav Adurkar, Dnyaneshwar Changdeo Bhanage, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20160331753Abstract: The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of formula I, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment.Type: ApplicationFiled: July 25, 2016Publication date: November 17, 2016Applicant: LUPIN LIMITEDInventors: Bhavesh DAVE, Rakesh Kumar BANERJEE, Samiron PHUKAN, Abhijit Datta KHOJE, Rajkumar HANGARGE, Jitendra Sambhaji JADHAV, Venkata P. PALLE, Rajender Kumar KAMBOJ
-
Patent number: 9447037Abstract: Disclosed are an alpha 7 nAChR receptor modulator compound, 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yljbenzenesulfonamide, its tautomeric form, its pharmaceutically acceptable salts, pharmaceutical compositions comprising the compound or a salt thereof, and a method of treating various diseases, disorders or conditions, for example, Alzheimer's disease, mild cognitive impairment, senile dementia, vascular dementia, dementia of Parkinson's disease, and attention deficit disorder.Type: GrantFiled: June 2, 2014Date of Patent: September 20, 2016Assignee: Lupin LimitedInventors: Neelima Sinha, Navnath Popat Karche, Ajay Ramchandra Tilekar, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9428499Abstract: The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of formula I, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment.Type: GrantFiled: March 11, 2013Date of Patent: August 30, 2016Assignee: LUPIN LIMITEDInventors: Bhavesh Dave, Rakesh Kumar Banerjee, Samiron Phukan, Abhijit Datta Khoje, Rajkumar Hangarge, Jitendra Sambhaji Jadhav, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9421165Abstract: The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.Type: GrantFiled: February 3, 2012Date of Patent: August 23, 2016Assignee: LUPIN LIMITEDInventors: Ashish Ashokrao Deshmukh, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirishkumar Kulkarni
-
Patent number: 9409898Abstract: The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.Type: GrantFiled: May 1, 2013Date of Patent: August 9, 2016Assignee: LUPIN LIMITEDInventors: Nageswara Rao Irlapati, Gokul Keruji Deshmukh, Nilesh Raghunath Khedkar, Kiran Chandrashekhar Kulkarni, Zubair Abdul Wajid Shaikh, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9399638Abstract: The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.Type: GrantFiled: May 1, 2013Date of Patent: July 26, 2016Assignee: LUPIN LIMITEDInventors: Nageswara Rao Irlapati, Zubair Abdul Wajid Shaikh, Vijay Pandurang Karche, Gokul Keruji Deshmukh, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9393247Abstract: Disclosed is a compound of formula I: wherein Z, m and R1-R6 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the ?7 subtype, in a subject in need thereof, as well as analogues, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereof, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.Type: GrantFiled: May 6, 2015Date of Patent: July 19, 2016Assignee: Lupin LimitedInventors: Neelima Sinha, Gourhari Jana, Sachchidanand Sachchidanand, Sanjay Pralhad Kurhade, Navnath Popat Karche, Anil Kashiram Hajare, Ajay Ramchandra Tilekar, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9388196Abstract: Disclosed is a compound of formula (I) wherein Y, Ring D, m and R1-R4 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the ?7 subtype, in a subject in need thereof, as well as pharmaceutically acceptable salts, polymorphs, solvates, and isomers thereofs, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.Type: GrantFiled: February 22, 2013Date of Patent: July 12, 2016Assignee: Lupin LimitedInventors: Neelima Sinha, Navnath Popat Karche, Anil Kashiram Hajare, Shridhar Keshav Adurkar, Bikramjit Singh Lairikyengbam, Firoj Aftab Raje, Ajay Ramchandra Tilekar, Baban Rupaji Thube, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: D789518Type: GrantFiled: July 8, 2014Date of Patent: June 13, 2017Assignee: LUPIN LIMITEDInventors: Vishwajit Bhide, Raghuram Amperayani Pattabhi, Rohini Pimple, Bishu Choubey
-
Patent number: D790684Type: GrantFiled: July 2, 2014Date of Patent: June 27, 2017Assignee: LUPIN LIMITEDInventors: Vishwajit Bhide, Raghuram Amperayani Pattabhi, Rohini Pimple, Bishu Choubey